Stock Events

Harmony Biosciences 

$33.9
41
+$0.6+1.8% Today

Statistics

Day High
33.95
Day Low
-
52W High
39.27
52W Low
18.61
Volume
262,549
Avg. Volume
428,911
Mkt Cap
1.93B
P/E Ratio
14.61
Dividend Yield
-
Dividend
-

Upcoming

30
JUL
Earnings

Earnings

30JulConfirmed
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Next
0.47
0.65
0.83
1.01
Expected EPS
0.704286
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HRMY. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap6.87B
Jazz Pharmaceuticals competes in the narcolepsy market, directly challenging Harmony Biosciences' key product, Wakix.
Avadel Pharmaceuticals
AVDL
Mkt Cap1.56B
Avadel Pharmaceuticals is developing treatments for narcolepsy, positioning it as a competitor in Harmony Biosciences' core market.
Axsome Therapeutics
AXSM
Mkt Cap4.03B
Axsome Therapeutics has a pipeline addressing central nervous system disorders, including narcolepsy, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
Teva Pharmaceutical Industries offers products for sleep disorders, including narcolepsy, competing with Harmony Biosciences.
Biogen
BIIB
Mkt Cap32.96B
Biogen focuses on neurological disorders and has a broad portfolio that could compete with Harmony Biosciences' treatments.
Sage Therapeutics
SAGE
Mkt Cap739.64M
Sage Therapeutics is developing therapies for central nervous system disorders, potentially competing with Harmony Biosciences.
Supernus Pharmaceuticals
SUPN
Mkt Cap1.66B
Supernus Pharmaceuticals has a focus on central nervous system diseases, including treatments for sleep disorders.
Palatin Technologies
PTN
Mkt Cap27.92M
Palatin Technologies is involved in developing treatments for various conditions, including those affecting the central nervous system, potentially competing with Harmony.

Analyst Ratings

47.25$Average Price Target
The highest estimate is $52.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Show more...
CEO
Employees
246
Country
US
ISIN
US4131971040

Listings

XNAS
US
HRMY